<SUBMISSION>
<ACCESSION-NUMBER>0000950133-07-005025
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20071220
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20071220
<DATE-OF-FILING-DATE-CHANGE>20071220
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>071317792
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>9920 BELWARD CAMPUS DRIVE
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
<PHONE>240-268-2000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>9920 BELWARD CAMPUS DRIVE
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w45174e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>Date of Report (Date of earliest event reported) December&nbsp;20, 2007</B></DIV>


<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>NOVAVAX, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of Registrant as specified in its charter)</B></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B> <BR>
<B>(State or other jurisdiction of<BR> incorporation or
organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26770</B><BR>
<B>(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-2816046<BR>
(I.R.S. Employer Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>9920 Belward Campus Drive <BR>
Rockville, Maryland</B><BR>
<B>(Address of principal executive offices)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20850<BR>
(Zip Code)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Registrant&#146;s telephone number, including area code:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"> <B>(240)&nbsp;268-2000</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
<B>(Former name or former address, if changed since last report.)</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</B></DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;8.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Other Events.</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On December&nbsp;20, 2007, Novavax, Inc. (the &#147;Company&#148;) announced interim results from a Phase I/IIa
human clinical trial of its pandemic influenza virus-like particle (VLP)&nbsp;vaccine candidate and will
conduct a publicly available conference call to discuss those results.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A copy of the press release is attached to this Current Report on Form 8-K as Exhibit&nbsp;99.1 and is
incorporated herein by reference.</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Exhibits
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibits</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated December&nbsp;20, 2007</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Novavax, Inc.<BR>
(Registrant)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">December 20, 2007&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/    Len Stigliano
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Len Stigliano&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer, Vice President and
Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w45174exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="w45174w4517401.gif" alt="(NOVAVAX LOGO)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tricia J. Richardson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Novavax, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">240-268-2031&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Novavax Announces Favorable Interim Results From Human Clinical Trial<BR>
For Its Pandemic Influenza Vaccine Program</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ROCKVILLE, MD (December&nbsp;20, 2007) &#151; Novavax, Inc. (NASDAQ: NVAX) announced today favorable interim
results from a Phase I/IIa human clinical trial of its non-adjuvanted pandemic influenza virus-like
particle (VLP)&nbsp;vaccine candidate.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Penny Heaton, MD, Chief Medical Officer and Head of Clinical Development stated, &#147;The initial
results from our Phase I/IIa study are promising and support further development of our pandemic
influenza vaccine through regulatory licensure. We are moving forward with a dose ranging study as
anticipated. These data illustrate the potential of the VLP platform to provide well tolerated
and effective vaccines against difficult viral targets, such as the H5N1 avian influenza strain.&#148;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In the initial stage of this study, seventy healthy adults 18 to 40&nbsp;years of age received two doses
of either 15 or 45 mcg of the H5N1 VLP vaccine candidate or a placebo. The goal was to evaluate
safety and immunogenicity, including hemagglutinin inhibition (HAI)&nbsp;and neutralizating antibody
responses.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The interim results indicate that the vaccine was well tolerated in all study groups. An
independent Data and Safety Monitoring Board (DSMB)&nbsp;reviewed the safety data and recommended that
Novavax proceed with the second stage of the study, in which the safety and immunogenicity of a
range of doses up to 90 mcg will be evaluated.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The vaccine also induced good immune responses. Among those individuals in the 45 mcg arm (N=35),
83% had neutralizing antibody against the H5N1 A/Indonesia/05/2005 avian flu strain after the
second vaccination. Sixty-three (63)&nbsp;percent had a 4-fold rise in neutralizing antibody from
baseline. In regard to HAI responses, 48% had a 4-fold increase in titer from baseline. All
subjects tested negative for antibodies to the H5N1 Indonesia strain before vaccination and no
responses were observed among individuals who received a placebo. The candidate vaccine also
induced responses against a different H5N1 virus, the A/Viet Nam/1203/2004 avian flu strain.
Evidence of immunologic activity was observed among subjects who received the 15 mcg dose (N=14);
75% had neutralizing antibody against the Indonesia strain. Immunological responses to the
neuraminidase (NA)&nbsp;or matrix 1 (M1) proteins were not measured in the interim analysis.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax&#146;s VLP vaccine consists of recombinant particles that closely mimic the influenza virus and
contain three immunologically important proteins HA, NA, and M1 from the H5N1 A/Indonesia/05/2005
avian influenza virus. The VLPs lack viral genetic material and therefore cannot replicate or
cause disease.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Commenting on the interim data, Dr.&nbsp;Rahul Singhvi, Novavax&#146;s President and CEO said, &#147;These data
support the vaccine as part of our contribution to pandemic flu preparedness planning. Novavax has
the potential to offer a safe and immunogenic vaccine that can be created in cell culture within 12
weeks of the emergence of a pandemic strain. We also offer a portable manufacturing platform that
lends itself to regional production. Such a vaccine solution, combined with our manufacturing
platform, provides opportunities for Novavax to assist countries in establishing their own pandemic
vaccine supply&#148;.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;In addition, these initial results from our pandemic trial bode well for our trivalent seasonal
influenza vaccine, which is expected to enter human clinical trials during the second quarter of
2008, pending completion of pre-clinical studies,&#148; he added.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Conference Call</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company will hold an investor conference call to discuss the data results at 10:00&nbsp;a.m. Eastern
Time on December&nbsp;20, 2007. The call will be hosted by Novavax President and Chief Executive Officer
Dr.&nbsp;Rahul Singhvi and other members of senior management. A question and answer session will
follow the financial results overview. The dial-in number for the conference call is USA and Canada
(888)&nbsp;812 8589 International: (913)&nbsp;312 0399.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A live audio webcast of the conference call will be available at www.novavax.com. Please connect to
this website at least 15 minutes prior to the conference call to ensure adequate time for any
software download that may be needed to hear the webcast. A replay of the webcast will be available
for 90&nbsp;days after the webcast and a replay of the conference call will also be available by
telephone beginning 1pm EST. December&nbsp;20, 2007. To access the replay, dial (888)&nbsp;203 1112 and
enter pass code 9037449.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Novavax</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax Inc. is committed to leading the global fight against infectious disease by creating novel,
highly potent vaccines that are safer and more effective than current preventive options. Using the
company&#146;s proprietary virus-like particle (VLP)&nbsp;and Novasome<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> adjuvant technologies, Novavax is
developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral
diseases. Novavax&#146;s particulate vaccines closely match disease-causing viruses while lacking the
genetic material to cause disease, which provides potential for greater immune protection at lower
doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid
mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Statements herein relating to future financial or business performance, conditions or strategies
and other financial and business matters, including expectations regarding clinical developments,
anticipated milestones, revenues, operating expenses and collaborations and partnerships are
forward-looking statements within the meaning of the Private Securities Litigation Reform Act.</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks
and uncertainties, which change over time. Factors that may cause actual results to differ
materially from the results discussed in the forward-looking statements or historical experience
include risks and uncertainties, including the Company&#146;s ability to progress any product candidates
in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and
other research and development activities; the scope, rate and progress of any clinical trials we
commence; clinical trial results; even if the data from pre-clinical or clinical trials is
positive, the product may not prove to be safe and efficacious; risks relating to the early stage
of Novavax&#146;s product candidates under development; uncertainties relating to clinical trials; risks
relating to the commercialization, if any, of Novavax&#146;s proposed product candidates; Novavax&#146;s
pilot plant facility is subject to extensive validation and FDA inspections, which may result in
delays and increases costs; dependence on the efforts of third parties; failure by Novavax to
secure and maintain relationships with collaborators; dependence on intellectual property;
competition for clinical resources and patient enrollment from drug candidates in development by
other companies with greater resources and visibility, and risks that we may lack the financial
resources and access to capital to fund our operations. Further information on the factors and
risks that could affect Novavax&#146;s business, financial conditions and results of operations, is
contained in Novavax&#146;s filings with the U.S. Securities and Exchange Commission, which are
available at http://www.sec.gov. These forward-looking statements speak only as of the date of this
conference call, and Novavax assumes no duty to update forward-looking statements.</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">###
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w45174w4517401.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w45174w4517401.gif
M1TE&.#EA.`$T`/<````Y>P!">P!"A`!*A`A"A`A*A`A*C!!*A!!*C!!2A!!2
MC!A*A!A2A!A2C!A:C"%2C"%:C"%:E"E:C"E:E"ECE#%:E#%CE#%CG#ECE#EC
MG#EKG$)KG$)SG$)SI4ISG$ISI4I[I5)SI5)[I5)[K5I[I5I[K5J$K6.$K6.,
MK6.,M6N$K6N,K6N,M6N4M7.,M7.4M7.4O7N4M7N4O7N<O82<O82<QHR<O8RE
MO8REQI2EQI2MQI2MSIRMQIRMSIRUSJ6USJ6]SJVUSJV]SJV]UK6]UK7&UK7&
MWKW&UKW&WKW.WL;.WL;6WL[.WL[6WL[6Y];6Y];>Y];>[][>Y][>[][G[^?G
M[^?G]^?O[^?O]^_O[^_O]^_W]_?O]_?W]_?W__?____W]__W____]_______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````.`$T```(_@#'"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@=5JE"96-'CAXW=NDR1HR7,21-HBSII4M(D!RU=`'S14R8
M+S1MXJPY<V`6)T)HG-A0X4&"!0H60,#P@46.(U)(LA2ST@M5DB-A?MQ:9>08
MFBO!DA3[]4M6K1M!KI2*%248,5=><MTHINU:@5GG<AUI4F7?DW^G>@$35R_'
MMF1ISMR"%FU=E2E/9I'2F&M?G&.L8M;\5DOEC5&R!.XK$,(#TZA/JS;]@VK9
M,6'$?(%=<PP7$JM5/VC])?9LW[!E#ZPBY(0%!@<(%#AP5`$#!0<:'#A0@,`!
M!QYH*)&*=R!;W*G#_E>`(AS,F-GFT9]_356*A=RH&]#0^75]^C%4,L#/;<%)
MR<S_6240&#0T$%YN0F3FFH`K=>=@%B+L9YH(6@B$V7GFH21&#`U(>-H$3;S6
MX!A5B-#A@:A-H(1W`MU$E8MA=&&"APUL((5LP-TDT'0\4M?C=`58((6#F!4)
M1A<<+,?C<@7T0)6``KHH(!4T8%#`E0<P@``#"4C70)=9)L4ED`0P$`(07%B8
MGGE=B/&#DDKV*,`-#H(%5H-@6:6#=3TJR<"*K]W9DPUQ_N@C`2OHI*B"`C71
M0*%]FD`3<&#Y9NF38QP!I*$%\,#2ISA2U<0#D/Y8P`DYA8'A>6(P,4&I_DMJ
M4$59BL)8$PY\^K@D`T74UYML-@GTW`)@#MME<P6XT)>+M`7[!1<?,(<4E]+Y
MX.NB/761`P7*9>DEF%\N\*V6SY$+W7(?*"$&3??1E(65TI4;70('<)!%G>C-
MAN=L2#(7;U()%$""5!=R]X44$H2)W)?D@OM$2;VMNA,8)Q00KG/S'B`!%)^"
M>E*##+Y09K%)!3FKQQ#'QD(!"S=';731A2@QFV,4(9W+"6QY5`$KL.O@3>8E
M\8"TSC4WW0_-`JB2L$DY)R;`X79YA(,I_3K&%M%>C-P!UM*WYFQ0D.!GTPQ,
MN^67WWII+K'2L4P#6WA1E0/+_[(='1(!=@S6_M+F*>'EO`Q(AT"OZ7E=VPPL
M;PEUF&SS/.!L?JU4A-WEGEU`#@(M+97FW55!`<S&/DH#>X`!-H830V.LM<Z/
MJ@`Y8+^2Q(._T;4LW0%(%]SY!@,$SOB7!\1`5:VO,\WVM&1[68`'%7*^:A?1
M@OL<U]<"71,35C+>Y;2UPPPN\@M4_C+/]XX%^100S-L`]X_&0*NMI*\4@\7@
MPKR!%J'F6Q\4":-=>_)9BMEK+(49Z!5@>ZJCEP<V]S$&=H<D/Z!=`Z:G,?)4
MJCP[60'=U#<M!`K0?)^:B0R6\[()P@P"_FF3@M@E,ND!C``GL(N=(&>\HJE-
M?3##7,<(=J1H.>=O_M0SG'F<0($"@,]_X;I2=0@0@.I,1WQ)N5AR5C`3_8W!
M!8D;5K@.@($KQ`A?\:N"!:2%-F)=CC0,PHH88&#$AMT0B:=RUJ($Q(,L(C$Z
M_EF4K5[$$[&E#2EQM`K\^H(Z#CI'<=,"9,]TMRHMD*!W9YL7(#UPKPN.X0='
M`==1'K6!644F93@R'@)MYZWI3&!(#M0)]+*D."XMP%J4FDT5-L`R'`[+.5=Z
MP`9,\`(9Q.`%(K#``I;SKX7)JP#ST1%8_+8]32+@``GRR\=F6)\(^DZ*$Z#"
MD[;9'2?T+P'DNMT/):F`!LB,FBL1(SG#IP!ZC8XDS*I4;<PS*@E*,@D*_K*:
M@$BB`I9-ZV:L9,`M#X#".7*S"AHH91E+)KR[0*$"%G/C="CP,+L(Z%?ZNJ46
MI:<SZ/3,+Q&S"=:8$\[I=`U&*,&BW2:H,^008`,Y@`(77(.7*R#A!:3:9/U,
MV`#"Y:L+)#C`(:_)@%.]):2E>UQ=*N9&0+JO)LP29$VP:"XM'<`"&X!9&>EU
M`M>@DR0TR.)0A[D!T4"I)'L4"`V$:LR=?4`JEPJIH\CYG`>(8%YGVQD+J"(H
M!S7A51K=$KF&@%:4B(!^ZW/.,'M*&I!1Y4)CT*C9`NL[7E&-55P``5VA8ZUV
MU0PZ&D6@Q6QPA<R%I38"<8+8-@FX+3WS?J`:_H,0M`I.G1W@E"E#67V<D#XD
M;E)F1F+5&)C06^EUJ@C^8AN8'K`$V(#2:DWHK1O!9`1N`@9^6:#E-<&4`*0M
M#:2QZ>=&&P!#*`R-I?)"(1C=,H8AU`V.%!C2;&Y@1*U!9P&>:E,#,[=?46IM
M.A,D60'*"ANIB"5ZZP-3$*T'5(M)\DM;.L`#@L`BG_WE*AH4E\L:AKN5J$0+
M"1UO=`K@`V>E)S;Y',,-`*S31Y$`:#/+(`&TMH`#4*`K697>B+M*DBC5Y"1@
MT"!EAZFLRS;+*IKZ%O<RX,5M_J8N8W!4*T&'-PV"]EL$V.M*@HL9';!XL@P@
MP,#&X#<P;ZD`+QC0_JH:Q$B-_DT#Y]4IL0B``S%<ICY:B!847^DKDB@!.93-
MV0%T8.>DX@BJJX(6RZ)HW+<63E5S:RHN0Y!*?8XAN[2-UP%\VK&^*(%44#S`
MZ-QT`$1B+'`K,NA*D&`[Y5ZU"JIBY%C&T$^M-0`!R.0FL\;"5+)!YZUD)F6X
M&N`$TG#Y*RU,\,7HA8-9UA*]#1``"?`W,R)EJ(8<?D%8)UM.@CXA?[%9)0`7
MK*$9S-AEWSJ`"*KX:(GIY$A13IM"HY-J9DGA<S2&3@,J"BJ,C@$).7O9].Y'
M&EN!P0N]UK!T)#"D,5P!`]WSWZG@6AL@HZ0#`27;,[T;5=>0A`K?3"RQ_B"`
M2C5A:#9_9BL0HPE4H1ZOG<DJ>,6O,@9'&G&H?WL`@G\WX"I`F<T9XN%`0D>N
M9%4!XN,L>@QU/=+0F1146O``XU2GI07TRM(RYROD*.9R30;N<JQBE@LDR-T#
MT`E*?%S7%ZBJ9.CH@$4-HDK*T;LS&7QJQ9I4=JH9):5++EKA62J`I#;#3=GA
M$&T%4(')0VD2KA-]P!42R!"2F_0'<,S`^B(8?JRT74W;<5X%D(!_$'VAX*Z9
MLAZ])',B.:P#$+;P"$8>]0IG7D,NK.>@5-IUBT<2(;Q\;1/G;TD^S4$%$QSM
MS:)"!2@_K!LW"&XH,<'-7Z8`R[_FW@\&4P%*_H"I4&'HX1(D%T$Y%O>/U27V
MQ4)`JOLK%;\5OUJ*TD)6$]@V%YC\^8550L)&B4@D%K4!1/!SIC>`_E5T+&!8
M&<=.!Z`!67`I6J!9_E-U)S4;R.5T`<8S<14_]$$?53`!AT<M!<"`SM47,E)?
MMJ<NIJ,9JA)!'%54[M-]^W4$Y%)2![!79!$#JU="7;(B\)0_YK%627=(!Y`#
M:M<L.L($\N8[P&9=+$$QSZ9@&3`KI%%'E.5M6]8NKR,&0U!CPV*!8`(=F$,:
MW`%]TH1M@E4`+&`>2*@P.C-,\\$@>49&QS)[ZS$["Q5.8.=]AK9[G[(%'$!V
M"78`%:!-NC<&1$!2_HQV.VGF%[MV6!K&/0\0(D52%HIQ5W_4)2$"-T\@7?TG
M,$<U0+(!!E```1&V4`?P5L3C&CBX.LCA77M8$TE@3(!3`'66*E^@3J'3)3$'
M0M34!;&!`\0D/<52?YXUB6L2=NL165!C@"L15K8G83*#%7I&-D]'*VO5@DEQ
M`$``BEC'A\%R`F6R."SU`'D$("2!:7>$'!9P,A0G!O44@=`Q>$''(LA%5\^$
M*CM!B2NS45K2)7B3/P56$ROS1O32`/4&5;.1!6,T2O1B`5F`?(!Q)!6#2-,C
M)$;8)F%E3!&6`-;W7=-4$^S"`LT!>-=T`-.F=8%B'^J!D&;X=2O@7+AH_FI%
M-69?,5).HV%T6!(RX'(V1"S.001&!I%HA5H:I#9?R)&C9Q/"(08ZD$7F,AT)
MTATJ$58\I6!`*70%)'5!*"Z`@G_,%"__8I)8^2)CD`0KM4E%-3H(J1*^-U1=
M@FMTPBAG)09F65M=6`!VQTU@XX%#-4XO8&+5ED[XYC)3!@'\QC=61$W!HHQL
M<WM:IBJS-8PPTV$"D5D!Y#]\IA)@\`)3]WO5Q2B.)9=#217[^(SDF%LJ404A
M]T^G$E6=$6)*5@`<@#\^,XFS]3<,(S`D88S15R;R1B_X=(Q%T@4AP#*:-$PB
MN!+A5C&L:'T.DD85\T\GQ#%QI2I"UG;C)WR!_BD&-Z`VK>1:R/$"51-+(J*8
M+5E4!U@6#399NH@!GK1*S70[UO(:.RF99=0KT"<50JDH&=:72(%'P@=58C!"
ME=4T%?0IYH%<3X,4C^(I^+<27/"'SK$V@U,KK&(5R#5*M2,P5N%CP4)J^J93
M")``4[-/8@`%'LB0!]`S*=D;?O9[9Z8LF/<IGT8R19=FMFABLQ%!MB=8V3AH
MP8%1Y!E+JL*87<*,7T$2T66/8?:"EHES]-)9ZT%?B158'>8\^LF$3^)'X:13
MSNEA7A`;3G`S50HS;\<68G`"X3=1G@1W$)1Q1;=N>Z-FE0D"T_<MSS0U9=@7
M5Y`!0L5!Z'D9D`:(_G>3-R#58`6Z,"$"'*YQ%7>E8](!`9?W.+0B!L3GEB2)
M2XQ5G1@4I")"68_RDGA1$S0P8QK%'`^P(DVG<0M6$SZ0)>@&>C806WMH9"#&
MI`TY*RQ9%SAA`K13.>K6$S4A!<6E-GCI<2W"$]D548@D-0Q!!"WS3T6U;L])
M<U1:.XIS551@'K(1H9DV3'):/*1Q!,1"D;@FJ@IAEKYU.S(0BFMV$E(`+]@:
M.I-5`!-`'G`%D!>D'HPYH6=V@"BF*@@54<E3`)2V2KG(9_=Q!$D8+\%7AKJ%
MIN85JZWW`?<B,2A6,T0S@]"X*G6$G:>I:F,P.U!C-Q*``SJ0`RF[LBK;_K(W
M\``:MS#,,36Q@7QC@*)D1RQ7>A)*D$E@>30MJIY!-4X,@P`KP`,MR[(LBP,)
M0[0PLS%#22LVISU_TT[>6506>V112SS_8:3&FIYS.ENUPUW/Y`-@$#TT.(%B
MH)K9]S>XI5L0NSE>!H\:EBRD)YS>"D#0,3IX\8>G.G%HA"E7$&+BF#/5<;C*
MD;A78AWT$C@NDXT@D!(=!QO7R89B.1`BX[C*PX"\J"^94KA_@[BBJQQ*4DRS
MV*Y4(P98%'$*%E`N@Q2(,H8F5R0Z4:1N-F*B>BE=P%219$(6``662#)TB!-=
M$+RX"4Y`"I$+PH1=H)6/.%0==K=K9H<C"3P$_D9F;4<NO3(B;>%E/>I*R`MH
MF40LY6IKDK1I08IB`N)^_&B%:_LYXS:KIH<5?J10W$6^X0NK.KM5WJDQ\N4S
MWGN'U/%+=PHXT_%V=K)FQ]:OQH2&E*H2FSBO`9<LQ;E=-3:?BC$&7E:*KI2-
M[OF@:200#!)!`,0PMT4>H,E#8D`%8Z1D\?*/\_-'![`!6^!<1K*V2+<VZWIX
MHR1OZ/5K^K5#AL6L`T6$JB<^S!$!0Q)*!90I3T0VW%95_1>?/$P=,U`7*%8$
MJ:/#D)<%23)9N,EIPNDKUT9T_ZIF_D9?8.PM1O&S22&E*T&L'VBU@"O"R,HH
MF(&S&A5%U*$"G\2(_OPRH':$+"\0!E>PD+AY`)X";L""`[_*BG_DGU0GDYI&
M6'*Y3;=IE]G(`2/AJVI3,GNE*HQ<O`Y6E6`<JW1+?]VCQ!KR!(`%9@0%*.^H
MR<AAK^17>L=X>C&+G@_L(EF04'DW'?PW)O.YF^;!F>#):#KK`A?;>&NF0E'F
MIU0L+P8)PB^B$JBCR3KKD)-73#7F?!JH3BZ\.(`VHO@;8>(W5!)UBBH$D9CF
MEO'B!%)@%.Q#;WI8$B0Q.8^K8>8<<-Z#%.0KCF53-`"-3"51!4FB458%I%+Q
MJN\7>)04*"MY']B&I"?FKAG:NQ8H?E**:/S#PZ'[`4?`'0=Q!3D@`6+%_D[3
M@BC[5*UKQKM(/`0)5RZYEE1W=VYM5QU-)``%T$0$,``_K1P[W=.'6Z"`%Y5]
M91[`*%FBL]346`#K=BD`,L1K@S$'P--,5`!8#=1#O=.D^[/^<TII.GV=.#!%
M&&0.=KN)-Y[E(3'^M:%@"SE`TR9J6C=;J6`8G"]B0(6)Y)\'%`(ZH`14D`5<
MT`58``5%$`,9L!PNQ)H54')8:G*3@W/V4ZPP8WT\%#%LZV8U9@(Y<`,X@`.@
M+=JD/=JC+=HY4,&_>8KE<UER_,/,40'"=)/`$TVU6H'?J242`-JGS=ND'=JF
MC0,Y('7^-V(T`(S_HUQ!0@64*!#.)F+`0R<Y_JHC],'`RI.[`"D0$4RW1>NX
MPTN)7;`"!/"Z\$P=1B0!&+`!&E`!Z:,<$F6*"1"`$2.]0#=2WE(_WX-+)Y!Y
M0PE6!_2S#&``#$<1:SAL'I0@Z'3,9.W=59P!%;*6+L(%AU65(VK0$\%,S]N/
M#Z"1QK(E0'E1.4%\YKLP5PDJU/TQISI!#ER>&"4&D=:[V+@`/3":C)(%)R``
M%+N,SV3>6-):%HQ+^`6FCY7+<$.]`+UGBD6BA:B4'QV!7W*LD@LQ'XIHP+*<
M&Z11!=`!%VLDU_-?Z"51!1"7>V0>DR>+)G2O6N=5J)432M5@20@=<TP=-`!O
M!4,27D8R.&FOWX;'_A==@&=,QO:!$O+W=SL,/!WM&X-Q:2@P'3$[+DW#-HGH
MXR6S&U$K3]R$)^KDKPD+/,R#,C81P_:+`)(:8^D;=AAE'D90U0/=BF`T$L;+
MA@*%2!`P!4/^((=EP8]B?]0T2-;3+&7^Z",.-<O3/,B'%14CZ5_G`5*(?!'#
MP):3N[5A<#5#.2YL-&I;I&:!$CKP`./-;9FJTI/L.]2Q`>KB;FGEH5:1D<U:
MI4W3*7"G$J,X=0.=+/_!2"W=:2=1O%\V3O5";7`3&Y,WS'^$AH';'64NDP1U
M3OJCF,Q2LUG@`7]WI`@//)%HQQ:?3IRW[LP1NQX&/PS,C("):&T2!AD6_NQ;
M4V*<*DBG<P+<?D`2!=W3<TP$8`$W4$E%HKXT'B7"\01M/*]DHX[+'EM81)!*
MD4?*M)(XS\CMM5)/V6&RBQ/RQU:"-?'KYR`H@7[*X\?W-Z-[(R50]JJ4_#L*
M-N-[VD!^UFH_1"]F]Z!+(]1"K=-=E309>+,3$`!N3]0$$-0!\':`3./#QP(6
MD/=*\I;3DV[GHM4,L`$XT'!K!EZTZGUI*@!OG]5,E/<!,.=S:15*<``!`-1W
M'P!=M7M>$Y@W+P9:P`&2C_<['0#KJ(>ND0-VW].?+]0A$&LZ"@8_8/<^K?<'
M4/7.P_#Z8AYBE/JQ[].RK],HD"$78K-4X=3L_@,N41F:8W`"U%_])V`"),`#
MYUYX;E("UO_]UW\"1S#=<IV/!RT$+K`!Z;-$@I_W67T`"V`!(6`#21!Y4.8\
M^WG)9'8")`#^U0\0)DY`$=-ES!@P7\9T$?.CQ`F($4T(="+&BY@Q7L9@O)AQ
M8QB%"3]^L3B&"(F(*4^8*,%DXY<P'#%24:%2I0D21PZ*3"@F3)<;#VV:H-'%
M8,F2"W>&5.B3I,8Q/U#:5$EB!16$7\",(0E2IM<N)0HP:'"@08(&"]`6F-#D
MH%*X;[<>C.E3#,R[8;@ZS;KS+<*W,;.*].IUC->$>@]VD8+DQXT7+E!`7.%B
MQ@TA2JX8/%B29U.-_DDY<X9[T>?;TYWU.MW:5>L7@W,_TK6(,29>O!Z1@MP8
MNN/AC<"#=Q%9&B/&P\B3=S[L.JO%K8+]=NYHN&-HWB*=;@<LEV[PX+?%R^2Z
M]6(5"P?0FC6;8$&#`AZJ]&;^M_[;ZEWO]BU^'_S?HPHCJ;G>\K*O,^24^PLI
MW/@#;3$((4QJP0/?TJJ\Z>Q3,*.\.LS-MY'H\\^_"S&<$+4*,83+L`J50RHT
M#G43<*344+31PK[&R^U"A8XHBP$%&#`+2+4(.&$T^Y"\CKP9^>H)I-L2ZQ#$
M[0PK;"^0$M)R(X-BZN)"SDJ\[B4=DV.JN:^>ZBNV,UO[3"F1NASP2AX%_AN3
MNXN\TBA.-.ETLSS<8KKH0XQX_-.@"P==C<H8L7-N.Q"53-,VYUJ[#3"2;"B@
MK+-^#/*``FZ@:\"W.$.J44JY$Y"CX&"DTE%574L5S=!@PA+#$I'$]5+"[JJR
MJUN!%=;)D+C"%-,_#>7*3E;Q1(XS[:R45:\2JVW-V1AY//9:WEYLM=DFZ>1K
MW%7[%+8UP(PBH8`#R&KO/2$5$*(O``]:$E5S4[6.1FG!E35?!^GSEKQ<(U2V
M32RG3?C77_DS]DTG<;64/%ACW%>T@W@\36,_[:6XT(D;I5$W5_TE]]]5N\UN
MS@&KV^\G,:1(+TA.T4(@@0,@<$+$"#'&M]QR_F'M=VB63^YKX))CA"O,9!V>
M=MB4GW8Z8&*179;BD?/[.-L_)0ZVZWOKQ!I/@45NF.%\54;YWXY>$X.(LA18
M($@$&+"Y@`TBC/`W4Z&"]DRTA2Z::'T'?W!@?)?.N&F>%A8WZH8;;[.IE:TF
M5,:69[VW[:X/WAAL@D.^\^*D!>?7\)-CQ38T,&@H((&ZSYI[`2`)T(DTN'SF
M>W&#Y]K=XLS1!!XCS@S[6V!&[U7<:X2?WICAJ*>&N/)DF<6<R>##[CS9SU74
M_FJS2?_V>K55#W?MU3'*0H2Q:F:@;KDID"))CWOV>ZD(M4N>S&8_Y)_K^A4,
M>>/['=-PY33H.<YYKM1[&.`8*+;P!<\Z6U,6\[HGIM"!;W0M*]L&4T>X\A$.
M7U"80+ODUJEV-2``(<!=W_;V+-[!18#>.AI4](>_W7`P?1%RX:FT9K;+<0Q7
MT*M4L287(LF)SF3#PQ?G5.0Y:H$.@)>K6/),%D+48;%P6Q,""AL@)!02(`8I
M(F,9S7A&-*91C6MD8QO=^$8XQE&.<Z1C'>UX1SSF48][Y&,?_?A'0`92D(,D
)9"$-V<:````[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
